Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +21 locations
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
NCT04262843
Recruiting
This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal organs and graft-versus-host disease (a complication after transplantation in which donor's immune cells recognize the host as foreign and attack the recipient's... Read More
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/06/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
Register for Updates
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
NCT04895761
Active Not Recruiting
The study seeks to establish the safety of neoadjuvant aromatase inhibitor with: DPX-Survivac, DPX-Survivac plus radiation, or DPX-Survivac with cyclophosphamide in stage I to III HR+HER2- breast cancer. There will be sequential enrollment into 3 arms with an anticipated N=6 participants per arm for N=18 participants in total. All participants will receive letrozole 2.5 mg daily during the 6 weeks of neoadjuvant therapy. Neoadjuvant therapy occurs weeks 1-6, with standard of care surgery taking... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Breast Cancer
Register for Updates
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
NCT02621021
Recruiting
Background: Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows them in a lab. Then they are returned to the person. Researchers think adding the drug pembrolizumab might make the therapy more effective. Objective: To test if adding pembrolizumab to cell therapy is safe and effective to shrink melanoma tumors. Eligibility: People ages 18-72 years with metastatic melanoma OF THE SKIN Design: Partic... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
03/06/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Melanoma
Register for Updates
ALL Adult Consortium Trial: Adult ALL Trial
NCT00476190
Active Not Recruiting
The purpose of this study is to determine the safety and effectiveness of a multi-drug chemotherapy regimen in adult patients with Acute Lymphoblastic Leukemia (ALL). We will use a regimen that is often used in pediatric patients and we will add drugs called PEG-asparaginase and E. coli asparaginase. PEG-asparaginase has been given as an injection in the past and has been used in treatment with both children and adults with ALL. Information from those other research studies suggests that intrave... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +14 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Allo HSCT for High Risk Hemoglobinopathies
NCT06872333
Recruiting
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Gender:
ALL
Ages:
55 years and below
Trial Updated:
03/06/2025
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Register for Updates
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
NCT02950259
Active Not Recruiting
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC) and to estimate the pathologic complete response rate to neoadjuvant anthracycline-based and non-platinum containing chemotherapy in patients with triple-negative breast cancer who have received the IRX-2 Regimen before chemotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
03/06/2025
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Breast Neoplasm, Breast Neoplasm, Male, Triple Negative Breast Cancer
Register for Updates
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06045247
Recruiting
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma
Register for Updates
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04049669
Recruiting
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ transplant, autoimmunity, and cancer. By inhibiting the IDO pathway, we hypothesize that indoximod will improve antitumor immune responses and thereby slow the growth of tumors. The central clinical... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
03/05/2025
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia +4 locations
Conditions: Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
NCT03910452
Active Not Recruiting
Background: CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives: To see if it is safe to use a related bone marrow donor who is only a partial match to a person with CGD. To see how well drugs given to a person before and after transplant help the body accept the transplant. Eligibility: People ages 4-6... Read More
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
03/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Granulomatous Disease
Register for Updates
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
NCT06364423
Recruiting
Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of these cancer cells. Researchers can modify a person's own immune cells (T cells) to target CD19. When these modified T cells are returned to the body-a treatment called anti-CD19 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: B-Cell Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic
Register for Updates
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
NCT05106296
Recruiting
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune responses, leading to improvement in clinical response with manageable overlapping toxicity. GCC2020 is... Read More
Gender:
ALL
Ages:
Between 6 years and 25 years
Trial Updated:
03/05/2025
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia
Conditions: Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
Register for Updates